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Mycoplasma pneumoniae (M. pneumoniae) belongs to the class Mollicutes and has
been recognized as a common cause of respiratory tract infections (RTIs), including
community-acquired pneumonia (CAP), that occur worldwide and in all age groups.
In addition, M. pneumoniae can simultaneously or sequentially lead to damage in the
nervous system and has been associated with a wide variety of other acute and chronic
diseases. During the past 10 years, the proportion of LRTI in children and adults,
associated with M. pneumoniae infection has ranged from 0 to more than 50%. This
variation is due to the age and the geographic location of the population examined
but also due to the diagnostic methods used. The true role of M. pneumoniae in
RTIs remains a challenge given the many limitations and lack of standardization of the
applied diagnostic tool in most cases, with resultant wide variations in data from different
studies. Correct and rapid diagnosis and/or management ofM. pneumoniae infections is,
however, critical to initiate appropriate antibiotic treatment and is nowadays usually done
by PCR and/or serology. Several recent reviews, have summarized current methods for
the detection and identification of M. pneumoniae. This review will therefore provide a
look at the general principles, advantages, diagnostic value, and limitations of the most
currently used detection techniques for the etiological diagnosis of a M. pneumoniae
infection as they evolve from research to daily practice.
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About 50 years ago, an outbreak of M. pneumoniae in a pediatric chronic care facility was
described (Baernstein et al., 1965). Twenty years earlier, the organism had been identified by Eaton
and since the early 1960s, it was clearly identified as a bacterium which was associated both in
children and adults with community-acquired infections of the respiratory tract (Lambert, 1964).
Since then, numerous reports have been published on the association of M. pneumoniae with
community-acquired infections (Waites and Talkington, 2004). Given the wide variations of data
from studies with equally wide variation of and lack of standardized diagnostic methods, the true
role ofM. pneumoniae in RTIs still remains a challenge.
Since its discovery, scientists have explored several strategies for an optimal diagnosis of a M.
pneumoniae infection in the laboratory to initiate an appropriate treatment. Because of its fastidious
nature, M. pneumoniae is not routinely cultured from respiratory specimens. Culture methods
have been the gold standard for diagnosis but are too insensitive producing a result after several
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days or even several weeks and are therefore not relevant
for the management of acute illness. Alternative diagnostic
procedures were developed: Detection of IgM and/or IgG
by ELISA, antigen detection by immunochromatography, and
nucleic acid amplification techniques (NAATs), mainly PCR,
although also isothermal amplification techniques such as LAMP
(loop-mediated isothermal amplification method) have been
developed. The utility of culture forM. pneumoniae was assessed
by comparing it to PCR and IgM serology in a large study (She
et al., 2010). Given the extremely low yield of culture and the wide
availability of NAAT and serology, the authors concluded that
culture for M. pneumoniae should be discontinued. Nowadays,
most studies are serology and/or PCR-based. Different clinical
specimens can be used as described in the review by Loens et al.
(2009) for the latter.
APPLICATION OF NAATS
PCR is accepted as a rapid diagnostic test. Few of the currently
available NAATs have been extensively validated against culture.
The sensitivity of NAATs is almost always superior to that of
traditional procedures and they are more and more considered
as the “new gold standard.”
An increasing body of literature describing the use of in-
house NAATs for detection of M. pneumoniae DNA or RNA in
various diseases is available with a great variation of methods
used from study to study, including variability of target (P1
adhesin gene, 16S rRNA, ATPase gene, protease gene, CARDS
toxin gene), NAAT (conventional, nested, real-time; monoplex
vs. multiplex; PCR vs. isothermal amplification technologies),
detection formats, and different platforms. An overview of the
literature on the use of NAATs to detect M. pneumoniae since
1989 is given in two reviews (Loens et al., 2003, 2010a).
Lately, efforts have been mainly emphasized on the
development of multiplex assays (Nummi et al., 2015; Shen
et al., 2015) and on the evaluation of commercially available
assays. Respiratory viruses and other so called “atypical bacteria”
are all responsible for RTIs that may produce clinically similar
manifestations. In order to reduce costs and hands-on-time,
multiplex NAATs for the simultaneous detection of 2, 3, or up
to more than 20 different respiratory pathogens in one tube
with a mixture of primers have been developed by some groups.
However, comparison between mono-and multiplex assays
has been rarely performed. Findings and conclusions result
frequently in contradictory and conflicting data concerning the
sensitivity and specificity of the multiplex NAATs compared to
the mono NAATs. This is not unexpected since the presence
of several pairs of primers may increase the probability of
mispairing resulting in non-specific amplification products
and the formation of primer-dimers. Furthermore, enzymes,
primers, and salt concentrations as well as temperature cyclings
required for each target may be slightly different. The results
of the proficiency panels (Loens et al., 2010b, 2012) described
previously seem to confirm that multiplex assays are somewhat
less sensitive than monoplex assays but until the number of
organisms present in clinical specimens of diseased individuals is
known, it is impossible to state whether the degree of sensitivity
attained is clinically acceptable.
Since the previous review (Ieven and Loens, 2013) newNAATs
became commercially available such as the Illumigene (Meridian
Bioscience, USA) kit. It has been proposed that industry-
produced assays in kit form result in better standardization.
The analytical sensitivity of the Illumigene assay was evaluated
by using 36 frozen stock cultures of M. pneumoniae reference
strains, and a collection of other microorganisms and human
DNA. (Ratliff et al., 2014). Serial dilutions of cultures with
a known CFU/ml defined the analytical sensitivity at ≤88
CFU/ml. Based on the results obtained with 214 archived
respiratory specimens, previously cultured for M. pneumoniae,
the clinical sensitivity and specificity were found to be 100
and 99%, respectively, after resolving discrepancies by PCR and
sequencing.
A second example of a test approved for the detection
of a number of respiratory viruses by the US Food and
Drug Administration is the Filmarray Respiratory panel
(bioMérieux, France). The Filmarray is a small desktop
closed single-piece flow real-time PCR system. It includes
automation of nucleic acid extraction, an initial reverse
transcription and multiplex PCR, followed by singleplex second
stage PCR reactions for the detection of 15 viral agents
including adenovirus, coronavirus HKU1, coronavirus NL63,
human metapneumovirus, rhinovirus/enterovirus, influenza
A/B, influenza A H1, AH1 2009, A H3, parainfluenza 1–4, and
respiratory syncytial virus (Poritz et al., 2011). In May 2012, the
US Food and Drug Administration expanded the use for the
Filmarray respiratory panel with the addition of B. pertussis, M.
pneumonia, andC. pneumoniae. The expanded panel detects now
a total of 17 viruses and three bacteria. The test requires 5min
hands-on-time and 65min instrumentation time. In 2013, a new
version of the Filmarray (version 1.7) was released (Doern et al.,
2013).
The Argene Respiratory MWSr-gene concept allows
the detection of numerous pathogens (Influenza A/B,
respiratory syncytial virus/human metapneumovirus,
rhinovirus/enterovirus, adenovirus/bocavirus, Chlamydia/
Mycoplasma pneumoniae, human coronavirus/parainfluenza
virus, Bordetella, Bordetella parapertussis) in the same run. In
addition, the diagnostic strategy can be adapted to the season:
searching for the most likely pathogens can be considered in 1st
stage, the remaining pathogens being searched for systematically
in a 2nd stage.
Pillet et al. (2013) compared six commercially available
multiplex assays for the diagnosis of respiratory pathogens. Two
out of six were also capable of detecting M. pneumoniae: the
RespiFinder SMART 22 (PathoFinder, The Netherlands) and
the Seeplex RV15 OneStep ACE detection and Pneumobacter
ACE detection (Seegene Inc, South Korea). Sensitivities and
specificities were calculated against the ArgeneChla/Myco
pneumo assay (bioMérieux, France). Sensitivity and specificity
were 70.0 and 100%, respectively, for the RespiFinder assay and
80.0 and 98.73% for the Seegene assay.
Dumke et al. compared four commercially available real-time
PCR assays recommended for use with the Roche LightCycler
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1.5 and 2.0 instruments [DiagenodeMycoplasma/Chlamydophila
pneumoniae real-time PCR (Diagenode, Belgium), GeneProof
M. pneumoniae (GeneProof, Czech Republic), BactoReal M.
pneumoniae (Ingenetix, Austria), LightMix kit M. pneumoniae
(TIB MOLBIOL, Germany)] for the detection ofM. pneumoniae
to results obtained with an in-house approach (Dumke and
Jacobs, 2014) by using serial dilutions of a cultured M.
pneumoniae strain tested in eight parallel runs and 37 clinical
specimens, previously found to be M. pneumoniae positive by
the in-house assay. All NAATs detected 20 colony forming
units (CFU)/5µl sample. Only the in-house-test (repMP1-based
approach) was able to detect 0.2 CFU/5µl sample. 37/37,35/37,
35/37, 34/37 M. pneumoniae positive clinical specimens were
confirmed by the Diagenode test, the Ingenetix and Lightmix
assay, and the GeneProof assay respectively.
An overview of commercially available NAATS for the
detection ofM. pneumoniae is presented in Table 1.
Since the calculation of the sensitivities of the commercial
multiplex assays was mainly dependent on DNA copy number,
further evaluation and standardization using an extended
number of clinical specimens that may have a low bacterial load
are needed. The use of an international standard developed by
the WHO for harmonization of Mycoplasma NAAT (Nübling
et al., 2015) or the yearly participation in the external quality
assessment (EQA) panel for M. pneumoniae and Chlamydophila
pneumoniae available from Quality Control for Molecular
Diagnostics (QCMD, United Kingdom) should be considered.
So far, it is unclear whether asymptomatic carriage of M.
pneumoniae in adults and children exists and if colonization
could be differentiated from infection by the current diagnostic
methods. There are only few data on the relation between the
bacterial load and the severity of infection. 405 asymptomatic
children and 321 children with a RTI were enrolled in a
cross-sectional study (Spuesens et al., 2013). Nasopharyngeal
washings and pharyngeal swabs were investigated by culture and
quantitative real-time PCR (qPCR). Serum was collected for IgM
and IgG ELISA. Neither qPCR, serology nor culture was capable
of differentiating colonization from infection. In 21.2 and 16.2%
of the asymptomatic and symptomatic children, M. pneumoniae
DNA was detected. In addition, persistence of M. pneumoniae
in the upper respiratory tract was shown for up to 4 months
by longitudinal sampling. A retrospective study investigated the
clinical significance of the M. pneumoniae bacterial load in
children with a M. pneumoniae pneumonia (Jiang et al., 2014).
The authors concluded that a high bacterial load was indicative
for a M. pneumoniae infection, whereas for a low bacterial load
the etiologic role ofM. pneumoniae remains to be determined.
Edin et al. developed a qPCR with duplex reactions targeting
eight bacteria, including M. pneumoniae, and six viruses
(Edin et al., 2015). Clinical specimens from the upper and
lower respiratory tract were used to compare the qPCR assay
with standard microbiological methods. The use of the qPCR
assay resulted in 113 positive identifications in 94 respiratory
specimens compared with 38 by using standard diagnostics. The
authors conclude that in parallel qPCR detection of the targeted
respiratory bacteria and viruses is feasible since a good technical
performance of the assay in clinical specimens was obtained.
In contrast to the above mentioned studies, Jain et al.
(2015) examined specimens from 2222 hospitalized children
with community-acquired pneumonia and 521 asymptomatic
controls for the detection of a variety of respiratory pathogens.
M. pneumoniae was detected in 8%, and in 3% or less of controls.
Another trend is the simultaneous detection of M.
pneumoniae and mutations associated with macrolide resistance
directly in clinical specimens (Ji et al., 2014; Liu et al., 2014;
Nummi et al., 2015; Zhao et al., 2015).
APPLICATION OF SEROLOGY FOR THE
DETECTION OF M. PNEUMONIAE
INFECTIONS
Serological methods, in particular enzyme-linked
immunosorbent assays (ELISA), are most widely used to
diagnose a M. pneumoniae infection. The complement
fixation test (CFT) has been replaced by assays which allow
for quantification of IgM, IgA, or IgG. However, the most
convincing evidence of an ongoing infection is a significant
increase in IgG or an IgG seroconversion in paired sera, collected
3–4 weeks apart (Nir-Paz et al., 2006). Although IgM antibodies
appear earlier than IgG antibodies, and are thus an attractive
alternative for diagnosis of a M. pneumoniae infection, one
should realize that IgM is not often produced in very young
children, in a proportion of primary infections and during
re-infections (Waites et al., 2008; Loens et al., 2010a).
Ten serological assays for the diagnosis of a M. pneumoniae
infection were recently evaluated by using 145 sera from 120
patients (Busson et al., 2013): SeroMP IgM and IgG (Savyon
Diagnostics), SeroMP Recombinant IgM, IgA and IgG (Savyon
Diagnostics), LIAISON M. pneumoniae IgM and IgG (Biotrin
International Ltd), M. pneumoniae IgM, IgA and IgG Medac
(Medac GmbH). A low IgM specificity and cross-reactivity
was noticed for the SeroMP recombinant and Liaison assay.
For IgA, the Medac assay tended to be less specific than the
SeroMP Recombinant assay. All four tests showed discrepancies
in the IgG measurements confirming results of previous studies
(Talkington et al., 2004; Beersma et al., 2005). In conclusion,
serology remains a diagnostic tool of choice but improvement
and standardization of the assays are still needed, especially for
the determination of IgG.
The clinical significance of a serologic test, both for IgM and
IgG, should be defined by studies of patients with a documented
infection and for whomdetailed information concerning the time
lapses between onset of disease and the collection of the serum
specimens are known.
A promising blotting technique improving the performance of
theM. pneumoniae serological assays has been described (Dumke
et al., 2012).
DETECTION OF M. PNEUMONIAE BY
BOTH NAATS AND SEROLOGY
Data from recent studies using PCR based methods and serology
published during the last decade in different patient populations
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TABLE 1 | Summary of commercially available single and multiplex PCR assays for detection of M. pneumonia.
Kit Manufacturer Assay type Detection procedure Pathogens targeted
M. pneumoniae
BDProbeTec ET
BD SDA Fluorescence M. pneumoniae
ASR MPN Cepheid PCR Real-time M. pneumoniae
Simplex M. pneumoniae Focus diagnostics PCR Real-time M. pneumoniae
GeneProof Mycoplasma
pneumoniae
GeneProof PCR Real-time M. pneumoniae
Loopamp Mycoplasma
pneumoniae DNA
amplification kit
Eiken chemical LAMP Turbidity M. pneumoniae
BactoReal Mycoplasma
pneumoniae
Ingenetix PCR Real-time M. pneumoniae
Illumigene Mycoplasma Meridian
BioScience
LAMP Turbidity M. pneumoniae
Venor MP Minerva BioLabs PCR Agarosegel
electrophoresis and
real-time
M. pneumoniae
M. pneumoniae LightMix kit TIB MolBIOL PCR Real-time M. pneumoniae
Cp/Mp tracer Affigene MX-PCR Real-time M. pneumoniae, C. pneumoniae
AID CAP bacterial assay AID GmbH MX-PCR ICT S. pneumoniae, H. influenzae, M. catarrhalis, C. pneumoniae, M.
pneumoniae, L. pneumophila
Chlamylege Argene,
bioMérieux
MX-PCR Hybridization C. pneumoniae, M. pneumoniae, Legionella spp
EasyPlex respiratory
pathogens B and C
Ausdiagnostics MX-PCR Real-time Influenza A, influenza A H1, influenza A H3, influenza A H5,
influenza B, RSV, rhinovirus, enterovirus, PIV 1-3, HAdV, hMPV,
HCoV 229E and OC43, B. pertussis, M. pneumoniae, C.
pneumoniae, L. pneumophila, L. longbeachae, Pneumocystis, H.
influenzae, S. pneumoniae
Respiratory Multi Well
System Chla/Myco pneumo
r-gene
BioMérieux 5 duplex
PCRs
Real-time Influenza A, influenza B, RSV, hBoV, HAdV, hMPV,
rhino/enterovirus, C. pneumoniae, M. pneumoniae
Diagenode
Mycoplasma/Chlamydophila
pneumoniae real-time PCR
kit
Diagenode Duplex PCR Real-time M. pneumoniae, C. pneumophila
Fast Track Respiratory
Pathogen assay
Fast-track
diagnostics
MX-PCR Real-time S. pneumoniae, S. aureus, H. influenzae, M. catarrhalis, Legionella
spp, M. pneumoniae, C. pneumoniae
ProPneumo-1 Hologic MX-PCR Real-time M. pneumoniae, C. pneumoniae
ProPneumo1+ Hologic MX-PCR Real-time M. pneumoniae, C. pneumoniae
Filmarray BioMérieux. MX-PCR Microarray Influenza A H1N1, influenza A H1, influenza A H3, influenza B, RSV,
hMPV, HCoV NL63, OC43, 229E, HKU1, HAdV PIV 1-4, HBoV,
rhino/enterovirus, B. pertussis, M. pneumoniae, C. pneumoniae
RespiFinder plus Patho Finder MX-PCR Capillary
electrophoresis
M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis,
Influenza A (H5, non-specific) and B, RSV A/B, PIV 1-4, rhinovirus,
3 HCoV, hMPV, HAdV
RespiFinder focus Patho Finder MX-PCR Capillary
electrophoresis or
microfluidics
M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis,
influenza A and B, RSV A/B, hMPV, HAdV
SmartFinder Patho Finder MX-PCR Real-time M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis,
influenza A and B, RSV A/B, PIV 1-4, HAdV, rhinovirus, 3 HCoV,
hMPV, HBoV
Seeplex PneumoBacter
ACE
Seegene Inc. MX-PCR Capillary
electrophoresis
S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, L.
pneumophila, B. pertussis
Seeplex RV/PB18 ASE Seegene Inc. MX-PCR Capillary
electrophoresis
S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, L.
pneumophila, Influenza A and B, RSV A/B, PIV 1-3, rhinovirus, 3
HCoV, HAdV, HBoV, enterovirus
Bold, FDA-approved test.
HAdV, human adenovirus; HBoV, human bocavirus; HCoV, human coronavirus, hMPV, human metapneumovirus; ICT, immunochromatographic test; LAMP, Loop-Mediated isothermal
amplification method; MX-PCR, multiplex PCR; PIV, parainfluenzavirus; qPCR, quantitative PCR.
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from around the world are summarized in the recent reviews
published by Ieven and Loens (Loens et al., 2010a; Ieven and
Loens, 2013) and updated in Table 2.
The availability of the very sensitive NAATs has in recent years
also put the often used serological tests in their right perspective
and allow a better interpretation of the serological test results
and their limitations such as the low sensitivity of IgM antibodies
in acute phase specimens and importance of the delay between
two serum samples. Studies in which also NAAT’s are used on
respiratory specimens should allow a better interpretation of the
serological test results.
A rapid response report from the Canadian Agency for Drugs
and Technologies in Health (Canadian Agency for Drugs and
Technologies in Health, 2015) presents the results of a literature
search in order to identify the diagnostic test accuracy, clinical
effectiveness, and cost-effectiveness of serum IgM and molecular
tests for the detection of M. pneumoniae in patients with a
respiratory infection1. Six relevant studies were identified, but no
evidence regarding the clinical effectiveness or cost-effectiveness
of a serum IgM test compared withmolecular tests was identified.
Zhang et al. conducted a systematic review and meta-analysis on
the diagnosis of M. pneumoniae by PCR and serology (Zhang
et al., 2011) and reported a significant heterogeneity between the
studies and inconsistent results as well.
Two studies compared the application of real-time PCR and
serology in children with pneumonia. In 2011, 54/290 children
were found to be positive by PCR (Chang et al., 2014), 44/182
were M. pneumoniae IgM positive. 12.6% of patients were found
to be M. pneumoniae positive by both tests at the same time.
Using PCR as gold standard, a sensitivity and specificity of
resp. 62.2 and 85.5% were obtained. The specificity could be
increased to 90.3% by increasing the cut-off without changing
the sensitivity of the IgM assay. A study conducted by Medjo
et al. (2014) applied PCR, culture, IgM and IgG in paired sera
for the detection of a M. pneumoniae infection in 166 children.
Using IgG serology as gold standard, the sensitivity of IgM, PCR,
and culture was found to be equal (81.8%), specificity was found
to be 100, 98.6, and 100% respectively. It was concluded that
during the acute phase of disease, detection of IgM antibodies
in combination with PCR allowed for a precise and reliable
M. pneumoniae diagnosis. A prospective study in children
with community-acquired CAP (Kakuya et al., 2014) compared
loop-mediated isothermal amplification, (LAMP), culture and
serology at first visit. Patients were defined positive if positive
by culture and/or sero-conversion or a four-fold increase in IgG
in paired sera. 31/191 patients met the criteria. Thirteen were
positive by culture and serology, 17 on culture only, and one
by serology only. A positive LAMP result was obtained for all
patients that were culture positive. The sensitivity and specificity
for LAMP, EIA, and the particle agglutination test, were 96.8,
38.7, 19.4, and 100%, 76.9 and 93.1%, respectively.
When establishing the etiology in 267 adult CAP-patients in
Norway, 10 were found to be M. pneumoniae positive: two by
1(2015). Serum IgM and Molecular Tests for Mycoplasma pneumoniae Detection:
A Review of Diagnostic Test Accuracy, Clinical Effectiveness, Cost-Effectiveness,
and Guidelines, Ottawa, ON.
serology, seven and one by PCR applied to a nasopharyngeal
flocked swab and an oropharyngeal flocked swab, respectively
(Holter et al., 2015).
AMPLIFICATION-FREE AND OTHER
TECHNOLOGICAL DEVELOPMENTS
Newer technologies such as microfluidics and the application
of nanotechnology offer the potential to an even more rapid
detection of important pathogens allowing even near-patient
testing. Since these technologies, as NAATs, do not require viable
organisms, and thus avoid any adverse effect of longer specimen
transport, they can be successfully applied to both the in-
and outpatient settings. Several companies currently possess the
technical expertise and research infrastructure to bring a useful
diagnostic testing approach to the clinical trial stage shortly.
Li et al. (2015) developed a colloidal gold-based immune-
chromatographic assay by using a pair of monoclonal antibodies
targeting a region of the P1 gene. When applied to 303 clinical
specimens from children suspected with a M. pneumoniae
infection, the sensitivity and specificity against real-time PCR
were 100 and 97.4%. This is in contrast to the results obtained
with a commercially available rapid antigen test targeting the
ribosomal protein L7/L12 (Ribotest Mycoplasma). Compared to
real-time PCR, a sensitivity and specificity of respectively 62.5
and 90.9% were obtained when applied to clinical specimens
(Miyashita et al., 2015). Based on these results, the authors
concluded that treatment decisions should not be taken based on
the Ribotest results alone.
Other amplification-free detection methodologies are
currently being developed as biosensing detection strategies: A
proto-type of an enzyme-free electrochemical genosensor on
nanostructured screen-printed gold electrodes (Garcia-Gonzalez
et al., 2015); A silver nanorod array-surface enhanced Raman
Spectroscopy biosensing platform was successfully applied for
the detection of M. pneumoniae in simulated and clinical throat
swabs (Henderson et al., 2014, 2015).
CONCLUSIONS
With the use of tools such as NAATs a greater understanding
of the etiology and epidemiology of M. pneumoniae is possible.
Taken into account the results obtained in recent studies, there
is more evidence that real-time NAATs are superior to other
M. pneumoniae detection strategies during the early phase of
infection. NAATs, however, cannot completely replace serology.
In epidemiological studies, serology is certainly more useful than
for the management of individual patients with LRTI or even
CAP since results are often delayed by the need for paired sera
to detect a seroconversion or a significant rise in titer; early in the
course of an infection, false-negative results often occur.
In case a specific IgM test is used, serology should not
completely be abolished despite the fact that IgM serology shows
a moderate sensitivity. Nowadays, a combination of the detection
of IgM antibodies and PCR may be the most optimal approach
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TABLE 2 | Summary of recent single and multiplex NAATs for detection of Mycoplasma pneumoniae published since the previous review, and previously
validated assays used as comparators.
Monoplex assays
Assay year
(references)
Assay
type
Detection
format
Gene target
(product size)
PCR assay used as
comparator for new assay
Non-PCR
comparator test
Specimens tested for validation of
sensitivity and or specificity
2012 (Zhao et al.,
2012)
PCR Real-time P1-gene (72) repMp1 and Mp181 Various bacterial species, bacterial
dilution series, well-defined clinical
specimens
2012 (Gotoh
et al., 2012)
LAMP Turbidity P1 operon
(NS) (Eiken
Chemical)
IgG seroconversion/
significant rise
Samples from 368 pneumonia patients
2013 (Chaudhry
et al., 2013)
PCR Real-time P1-gene (534) Conventional PCR (NS) IgM, IgG and IgA
serology
Dilution series, respiratory samples from
CAP-patients,
2013 (Schmitt
et al., 2013)
PCR Real-time ptsI (160) LightMix kit M. pneumoniae
(TIB MOLBIO), M.
pneumoniae analyte specific
reagent (Focus diagnostics),
(Dumke et al., 2007)
Bacterial dilution series, spiked clinical
specimens, well-defined clinical
specimens
2014 (Liu et al.,
2014)
PCR Cycleave 23S rDNA
(Takara BioInc)
(Ieven et al., 1996) Various bacterial species, bacterial
dilution series, clinical specimens
2014 (Ratliff et al.,
2014)
LAMP Turbidity Illumigene
assay (208)
2nd real-time PCR and
sequencing
Culture Various bacterial species, bacterial
dilution series, 214 culture
positive/negative specimens
2014 (Medjo
et al., 2014)
PCR Real-time P1 (125) IgM and IgG serology,
culture
Specimens from CAP-patients
Multiplex assays
Assay year
(references)
Assay
type
Detection format Specimens tested for validation of sensitivity and or specificity
2013 (Puppe
et al., 2013)
MX-PCR ELISA Culture supernatans of the organisms, clinical specimens from frozen stocks, prospectively included
nasopharyngeal aspirates
Pathogens targeted: enterovirus, influenza A, influenza B, RSV, PIV 1-4, HAdV, rhinovirus, hMPV,
HCoV, reovirus, M. pneumoniae, C. pneumoniae, B. pertussis, B. parapertussis, L. pneumophila
2013 (Simões
et al., 2013)
MX-PCR Affimetrix Chip-image file Clinical specimens simultaneously investigated by culture and two commercially available assays:
the Eragen assay and the Luminex RVP
Pathogens targeted: 72 pathogens
2013 (Weinberg
et al., 2013)
MX-PCR TAC-array Well-defined clinical specimens analyzed by individual real-time PCRs
Pathogens targeted: HAdV, hMPV, PIV1-4, influenza A, influenza B, influenza C, RSV, rhinovirus,
HCoV OC43, 229E, NL63, HKU1, enterovirus, B. pertussis, C. pneumoniae, H. influenza, L.
pneumophila, M. pneumoniae, S. pneumoniae, S. pyogenes
2014 (Hirama
et al., 2014)
MX-PCR Real-time DNA dilution series, welldefined clinical specimens from CAP-patients
Pathogens targeted: S. pneumoniae, H. influenza, M. catarrhalis, P. aeruginosa, K. pneumoniae, E.
coli, S. aureus, M. pneumoniae, C. pneumoniae, C. psittaci, C. burnetii, Legionella spp, L.
pneumophila, B. pertussis, M. tuberculosis, M. intracellulare, M. avium, M. kansasii, P. jeroveci,
Nocardia spp, metallo-beta-lactamase, MRSA
2014 (Ji et al.,
2014)
MX-PCR Agarose gel electrophoresis Various bacterial pathogens, bacterial dilution series, confirmation by sequencing, well-defined
clinical specimens
Pathogens targeted: M. pneumoniae and associated macrolide resistance
2015 (Zhao et al.,
2015)
Duplex
PCR
Real-time Pathogens targeted: M. pneumoniae and genotyping
2015 (Shen et al.,
2015)
MX-PCR Resequencing microarray Pathogens targeted: S. pneumoniae, M. pneumoniae, H. influenza, K. pneumoniae, M. catarrhalis,
S. aureus, P. aeruginosa, M. tuberculosis, N. meningitidis, Group A Streptococci
2015 (Nummi
et al., 2015)
MX-PCR Real-time Pathogens targeted: M. pneumoniae, C. pneumoniae and mutations associated with macrolide
resistance
HAdV, human adenovirus; HBoV, human bocavirus; HCoV, human coronavirus; hMPV, human metapneumovirus; PIV, parainfluenzavirus; MX-PCR, multiplex PCR; LAMP, Loop-mediated
isothermal amplification; TAC, Taqman Array Card.
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for early diagnosis of a M. pneumoniae infection, especially in
children.
The implementation of quantitative tests could shed further
light on the relation between bacterial load and the seriousness
of the disease, produce useful prognostic information and help
in the differentiation between colonization and infection. More
information could be gathered on the length of the post infection
carrier state as well as on the importance of subclinical infections
and how prone these are for spreading infection.
It remains important to recognize the urgent need for the
adoption of a more unified and consistent diagnostic approach
for current and future investigations. Therefore, a common set of
recommendations should be developed.
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